



NIH funding opportunities



Faculty of Medicine and Health Sciences: Research Development and Support 21 Oct 2019 (#35)

[Click on blue [hyperlink](#) for further information]

The NIH funding opportunities listed below are only a **selection** of pre-screened, currently open health funding opportunities for which **South African institutions are eligible to apply**. For a comprehensive selection of NIH funding opportunities, please visit www.grants.nih.gov or www.sun.ac.za/RDSfunding (current & archive).

Confirm your intent to apply ASAP, but not later than 60 days before the submission date.

Tygerberg Campus: cdevries@sun.ac.za • Stellenbosch Campus lizelk@sun.ac.za

Important Notices & News

- **NIH Operates Under a Continuing Resolution [NOT-OD-20-003](#)**. The Department of Health and Human Services (HHS), including NIH, operates under the “Continuing Appropriations Act, 2020 and Health Extenders Act of 2019” (Public Law 116-59) signed by President Trump on September 27, 2019. Continuing the procedures identified under [NOT-OD-19-031](#) and consistent with NIH practices during the CRs of [FY 2006 – 2019](#), the NIH will issue non-competing research grant awards at a level below that indicated on the most recent Notice of Award (generally up to 90% of the previously committed level). Upward adjustments to awarded levels will be considered after FY 2020 appropriations are enacted, but NIH expects institutions to monitor their expenditures carefully during this period.
- **Notice of Special Interest [NOT-MH-19-055](#): NIMH’s Interest in Early Stage Clinical and/or Mechanistic Trials in Posttraumatic Psychopathology, Directed at Testing FAAH Inhibitors**. NIMH is issuing this Notice of Special Interest (NOSI) to highlight its interest in supporting early stage intervention development and/or [Basic Experimental Studies with Humans](#) to investigate fatty acid amide hydrolase (FAAH) inhibitors in posttraumatic psychopathology.

1. U.S. and Low- and Middle-Income Country (LMIC) HIV-Associated Malignancy Research Centers (Clinical Trials Optional)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [RFA-CA-20-001](#)

Type: U54

Application Due Date: January 10, 2020. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The purpose of this Funding Opportunity Announcement (FOA) is to support research on human immunodeficiency virus (HIV)-associated cancers in low- and middle-income countries (LMICs) through the formation of collaborative partnerships between investigators in United States (U.S.) and investigators in LMICs. The FOA solicits applications for Specialized Center Cooperative Agreements (U54) for research on HIV-associated cancers from research institutions in the U.S. and LMICs. These partnerships are referred to as HIV-Associated Malignancy Research Centers (HAMRCs). Each proposed U54 HAMRC should be based upon partnerships involving at least one U.S. institution and institutions from at least two or more LMICs. Each HAMRC application is required to propose between two to three research projects that address questions in one scientific theme (e.g. viral-associated cancers) that is relevant to HIV-associated malignancies in LMICs or the U.S. The proposed projects may range, as appropriate, from basic research to translational efforts as well as to population and implementation studies. Mechanistic clinical studies that meet NIH’s definition of a clinical trial will be allowed. In addition, the proposed U54 HAMRC must include an Administrative Core and a Developmental Core.

Budget: The NIH intends to commit \$6,100,000 in FY 2020 to fund five to six awards. Application budgets need to reflect the actual needs of the proposed project but must not exceed \$800,000 per year in direct costs.

2. Human-Animal Interaction (HAI) Research (Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [PAR-20-031](#)

Type: R01

[PAR-20-032](#)

R03

[PAR-20-033](#)

R21

Application Due Date: December 20, 2019; November 30, 2020; November 30, 2021. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: This Funding Opportunity Announcement (FOA) invites grant applications for research to examine 1) the impact of HAI on typical and atypical child development and health; 2) the evaluation of animal-assisted intervention for children and adults with disabilities or in need of rehabilitative services; 3) the effects of animals on public health, including cost effectiveness of involving animals in reducing and preventing disease.

Budget: R01 - Budgets are limited to \$499,999 Direct Costs per year. Application budgets should reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years. R03 - Direct costs are limited to \$50,000 per year. The maximum project period is two years. R21 - Direct costs are limited to \$275,000 over a two-year period, with no more than \$200,000 in direct costs allowed in any single year.

3. HIV-associated Non-Communicable Diseases Research at Low- and Middle-Income Country Institutions (R21 Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [PAR-20-030](#)

Type: R21

Application Due Date: December 15, 2019; December 3, 2020. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The goal of this program is to support locally relevant research in critical areas of HIV-associated non-communicable diseases (NCDs) at Low- and Middle-Income Country (LMIC) Institutions, to enhance research capacity and build a network of researchers both within and across LMICs to address this critical burden. This initiative is expected to stimulate new research on the interplay between HIV and development of NCDs in persons living with HIV (PLWH). This includes exploratory studies to uncover the extent to which HIV infection influences the etiopathogenesis of the NCDs; and to identify and develop appropriate approaches for effective diagnosis, prevention, therapeutic interventions and integrated clinical care for PLWH with the comorbid conditions. Applicants should develop their studies in keeping with the NIH HIV/AIDS Research Priorities (<https://grants.nih.gov/grants/guide/notice-files/NOT-OD-15-137.html>). Research teams should contain an appropriate mix of expertise to accomplish the proposed studies, including partnerships between HIV and NCD researchers who can initiate new ideas and determine feasibility of novel approaches to understand and reduce the long-term suffering from the comorbid disorders. Applicants will also be asked to address the needs of collaborating LMIC institutions to develop capacity for carrying out research in this field.

Budget: The combined budget for direct costs for the two-year project period may not exceed \$275,000. No more than \$150,000 may be requested in any single year. The budget request must reflect the actual needs of the proposed project

4. Fundamental Mechanisms of Affective and Decisional Processes in Cancer Control (Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [PAR-20-034](#)

Type: R01

Application Due Date: [Standard dates](#) Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The purpose of this Funding Opportunity Announcement (FOA) is to encourage projects to generate fundamental knowledge of affective processes. Basic affective science projects should have key consequences for single (e.g., cancer screening) and multiple (e.g., adherence to oral chemotherapy regimen) event decisions and behaviors across the cancer prevention and control continuum. The FOA is expected to encourage collaboration among cancer control researchers and those from scientific disciplines not traditionally connected to cancer control applications (e.g., affective and cognitive neuroscience, decision science, consumer science) to elucidate perplexing and understudied problems in affective and decision sciences with downstream implications for cancer prevention and control.

Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years

5. Integrative Research on Polysubstance Abuse and Disorder (Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [PAR-20-035](#)

Type: R61/R33

Application Due Date: March 17, 2020, July 17, 2020, November 17, 2020, March 17, 2021, July 19, 2021, November 17, 2021, March 17, 2022, July 19, 2022, November 7, 2022 Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: This Funding Opportunity Announcement (FOA) is supported by Collaborative Research on Addiction (CRAN) at the National Institutes of Health (NIH), a trans-NIH partnership composed of the National Institute on Alcohol Abuse and Alcoholism (NIAAA), the National Institute on Drug Abuse (NIDA), and the National Cancer Institute (NCI). The intent of this FOA is two-fold: (1) characterize how the neurobiological alterations, associated behaviors, and public health consequences arising from polysubstance use differ from, or are similar to, those observed in single drug use; (2) promote integrative polysubstance research along a translational pipeline, consisting of basic science research in animals, human-based laboratory investigations, and epidemiological studies. These dual objectives will be accomplished with an Exploratory/Developmental Phased Award (R61/R33) mechanism, where polysubstance research can occur in any of these translational stages during the R61 phase and these findings will be rapidly back- or forward-integrated into another stage during the R33 phase, permitting accelerated bi-directional research exchange.

Budget: Application direct costs are limited to \$300,000 during each year of the R61 phase and \$500,000 during each year of the R33 phase. The project period is limited to 2 years for the R61 phase and up to 3 years for the R33 phase. The total project period may not exceed 5 years.

Brief definitions of some NIH grant mechanisms: [comprehensive list of extramural grant and cooperative agreement activity codes](#)

Research Development and Support Division (RDSD),
Faculty of Medicine and Health Sciences, Stellenbosch University
5th Floor, Teaching Block, Tygerberg Campus.
Enquiries: *Christa*
e: cdevries@sun.ac.za | t: +27 21 938 9838

Afdeling Navorsingsontwikkeling/Division for Research Development (DRD)
Stellenbosch University
2038 Wilcocks Building, Ryneveld Street
Enquiries: *Lizél*
e: lizelk@sun.ac.za | t: +27 21 808 2105